Evidence map›Paper›PMID 31100553›Full record

SynthesisThe journal of allergy and clinical immunology. In practice

Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity.

Lily Li, Tanya Laidlaw

Abstract readLetterSystematic Review
In one paragraph

Synthesis in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. How to Define and Manage Low-Risk Drug Allergy Labels.The journal of allergy and clinical immunology. In practice · 2024
    Review
  9. A case of possible anaphylaxis to ASA and structurally unrelated NSAIDs.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023
    Article
  10. Article
  11. Article
  12. Impact of reported NSAID "allergies" on opioid use disorder in back pain.The Journal of allergy and clinical immunology · 2021
    Article
  13. Article
  14. Lack of Major Involvement of CommonFrontiers in pharmacology · 2021
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lily LiDivision of Rheumatology, Allergy and Immunology, Department of Medicine, Brigham and Womens Hospital, Boston, MA. Electronic address: lli39@bwh.harvard.edu.
Tanya LaidlawDivision of Rheumatology, Allergy and Immunology, Department of Medicine, Brigham and Womens Hospital, Boston, MA.

Funding

Therapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Maria Gutierrez-Arcelus · 2011 to 2026
$29.1M
IMMUNOLOGIC BASIS OF RESISTANCE AND HYPERSENSITIVITYT32AI007306 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Nora Amanda Barrett, Joshua A Boyce · 1985 to 2026
$12.2M
Prostaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory DiseaseR01HL128241 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LAIDLAW, TANYA MARIA · 2015 to 2019
$2.2M
NHLBI NIH HHS R01 HL128241NIAID NIH HHS T32 AI007306NIAID NIH HHS U19 AI095219
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCelecoxibCross ReactionsCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDrug HypersensitivityHumansAnti-Inflammatory Agents, Non-SteroidalCelecoxibCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase Inhibitors

Identifiers

PMID31100553
PMCPMC7328117

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.